4 Midcap Upper Quarter of 52-Week Range Stocks to Watch for Future Multibagger Potential: Fortis Healthcare, Sona BLW, Navin Fluorine and Ajanta Pharma

Upper quarter of 52-week range stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Fortis Healthcare, Sona BLW, Navin Fluorine and Ajanta Pharma meet that test, with market caps from Rs 43,550 crore to Rs 57,814 crore and Fortis Healthcare offering the biggest five-year price gain at 241.47%. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a share price in the upper quarter of its 52-week range, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a share price in the upper quarter of its 52-week range, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening upper quarter of 52-week range stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 28 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Upper Quarter of 52-Week Range Stocks and Why Do They Attract Multibagger Interest?

Upper quarter of 52-week range stocks are shares that trade in the top quarter of the distance between their yearly low and yearly high, a zone that markets usually reserve for businesses with strong momentum. The four here cover hospitals, specialty chemicals, pharmaceuticals and auto components.

A price near the top of its yearly range shows that buyers are in control, and profit growth in both the year and the latest quarter gives the move a solid base. For upper quarter of 52-week range stocks, both FY26 and the latest quarter showed growth. Whichever way you read upper quarter of 52-week range stocks, the common thread is rising profit backed by complete financial data. A sensible way to study upper quarter of 52-week range stocks is to look at profit growth, returns and valuation side by side. Below, each of upper quarter of 52-week range stocks gets its own breakdown of growth, returns and valuation. Treat upper quarter of 52-week range stocks as a research list, since share prices and rankings change with every earnings season.

Upper Quarter of 52-Week Range Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 28 October 2026. Ajanta Pharma combines the lowest PE of the group, 38.37, with the highest return on equity, 23.33%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Fortis Healthcare	759.50	57,814	54.01	60.75	10.53%	0.35	565.00 to 759.50
Sona BLW Precision Forgings	879.45	57,251	83.46	37.33	10.70%	0.07	434.40 to 879.45
Navin Fluorine International	8,501	44,095	55.84	36.42	16.69%	0.32	4,772.20 to 8,949.50
Ajanta Pharma	3,459.80	43,550	38.37	36.35	23.33%	0.06	2,380.20 to 3,796.00

Fortis Healthcare: Five-Year Gain of 241.47%

Fortis Healthcare operates a chain of hospitals and diagnostic centres across India. It reported FY26 revenue of Rs 9,178.50 crore, up 16.93% year on year, and net profit of Rs 1,064.19 crore, up 31.48%. Net profit has compounded at 7.73% a year since FY22, while revenue has grown 12.43% a year. Operating margin was 22.41% in FY26. The debt-to-equity ratio is 0.35.

In the June 2026 quarter, revenue rose 17.29% to Rs 2,559.50 crore and net profit grew 2.26% to Rs 272.80 crore. The share price has gained 241.47% over five years. Domestic institutions raised their holding from 29.79% in June 2025 to 32.23% in June 2026. The stock trades at a PE of 54.01 against an industry PE of 60.75, below the sector average.

Sona BLW: Revenue Up 24.19% in FY26

Sona BLW makes differential gears, motors and drive systems for electric and conventional vehicles for customers around the world. It reported FY26 revenue of Rs 4,572.11 crore, up 24.19% year on year, and net profit of Rs 629.19 crore, up 4.92%. Net profit has compounded at 14.86% a year since FY22, while revenue has grown 20.75% a year. Operating margin was 25.91% in FY26. The debt-to-equity ratio is 0.07, which keeps interest costs low.

The stock trades at a PE of 83.46 against an industry PE of 37.33. In the June 2026 quarter, revenue rose 49.27% to Rs 1,336.07 crore and net profit grew 46.67% to Rs 178.51 crore. The share price is up 70.74% over the past year. Domestic institutions raised their holding from 34.59% in June 2025 to 41.61% in June 2026.

Navin Fluorine: 26.02% Profit CAGR Since FY22

Navin Fluorine International makes specialty fluorochemicals, refrigerant gases and contract research and manufacturing services. It reported FY26 revenue of Rs 3,379.19 crore, up 41.20% year on year, and net profit of Rs 663.56 crore, up 129.92%. Net profit has compounded at 26.02% a year since FY22, while revenue has grown 22.66% a year. Operating margin was 34.41% in FY26. The debt-to-equity ratio is 0.32.

In the June 2026 quarter, revenue rose 46.11% to Rs 1,080.17 crore and net profit grew 107.66% to Rs 243.31 crore. The share price has gained 111.47% over five years and 61.62% over the past year. Foreign investors raised their holding from 21.98% in July 2025 to 23.73% in June 2026. The stock trades at a PE of 55.84 against an industry PE of 36.42, with a return on equity of 16.69%.

Ajanta Pharma: Return on Equity of 23.33%

Ajanta Pharma sells branded generics in ophthalmology, dermatology, cardiology and pain management in India, Africa and Asia. It reported FY26 revenue of Rs 5,624.93 crore, up 18.60% year on year, and net profit of Rs 1,056 crore, up 14.73%. Net profit has compounded at 10.33% a year since FY22, while revenue has grown 12.94% a year. Operating margin was 28.74% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

The stock trades at a PE of 38.37 against an industry PE of 36.35, with a return on equity of 23.33%. In the June 2026 quarter, revenue rose 27.68% to Rs 1,696.86 crore and net profit grew 30.89% to Rs 334.22 crore. The share price has gained 125.31% over five years and 35.42% over the past year. Domestic institutions raised their holding from 17.90% in September 2025 to 21.94% in September 2026.

Upper Quarter of 52-Week Range Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these upper quarter of 52-week range stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	4-Year Net Profit CAGR	Operating Margin (Latest Quarter)
Fortis Healthcare	9,178.50	1,064.19	16.93%	12.43%	7.73%	22.22%
Sona BLW	4,572.11	629.19	24.19%	20.75%	14.86%	25.23%
Navin Fluorine	3,379.19	663.56	41.20%	22.66%	26.02%	37.52%
Ajanta Pharma	5,624.93	1,056	18.60%	12.94%	10.33%	30.41%

Check the Univest Screener for live data on these upper quarter of 52-week range stocks

Institutional Holding in Fortis Healthcare, Sona BLW, Navin Fluorine and Ajanta Pharma

Institutional holding shows who is backing these upper quarter of 52-week range stocks alongside the promoter. The table uses the latest reported quarter for each. Sona BLW has the deepest institutional backing, with FII and DII together holding 65.22% as of June 2026. Domestic institutions increased their holding over the past year in Fortis Healthcare (from 29.79% to 32.23%), Sona BLW (from 34.59% to 41.61%) and Ajanta Pharma (from 17.90% to 21.94%).

Stock	Promoter	FII	DII	Public	Quarter
Fortis Healthcare	31.17%	25.20%	32.23%	11.40%	June 2026
Sona BLW	28.01%	23.61%	41.61%	6.77%	June 2026
Navin Fluorine	27.08%	23.73%	28.46%	20.73%	June 2026
Ajanta Pharma	63.47%	7.63%	21.94%	6.96%	September 2026

Risks to Weigh in Upper Quarter of 52-Week Range Stocks

Being careful with upper quarter of 52-week range stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Sona BLW trades at a PE of 83.46 against an industry PE of 37.33, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Upper Quarter of 52-Week Range Stocks

Picking from upper quarter of 52-week range stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (36.35 to 60.75) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Fortis Healthcare, Sona BLW, Navin Fluorine and Ajanta Pharma live prices.

Conclusion

Among upper quarter of 52-week range stocks, Fortis Healthcare stands out for the biggest five-year price gain at 241.47%, Sona BLW for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.07, Navin Fluorine for the fastest profit growth, 26.02% a year since FY22 and Ajanta Pharma for the highest return on equity at 23.33%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing upper quarter of 52-week range stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Upper Quarter of 52-Week Range Stocks to Watch

Which are the best upper quarter of 52-week range stocks to watch for multibagger potential?

Ans. Fortis Healthcare, Sona BLW, Navin Fluorine and Ajanta Pharma are the 4 names this list highlights, with market caps of Rs 57,814 crore, Rs 57,251 crore, Rs 44,095 crore and Rs 43,550 crore respectively. Fortis Healthcare is notable for the biggest five-year price gain at 241.47%. Sona BLW stands out for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.07. Navin Fluorine offers the fastest profit growth, 26.02% a year since FY22. Ajanta Pharma brings the highest return on equity at 23.33%. These are watchlist names for upper quarter of 52-week range stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Ajanta Pharma a good stock for long-term investors?

Ans. Ajanta Pharma has a return on equity of 23.33%, a PE of 38.37 against an industry PE of 36.35 and a market cap of Rs 43,550 crore. Net profit has compounded at 10.33% a year since FY22, and FY26 revenue rose 18.60% while June 2026 quarter net profit grew 30.89%. Long-term returns in upper quarter of 52-week range stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Navin Fluorine become a multibagger from here?

Ans. Navin Fluorine has already gained 111.47% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in upper quarter of 52-week range stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 26.02% a year since FY22, and FY26 revenue rose 41.20%. At a PE of 55.84 against an industry PE of 36.42, valuation should be checked against that growth before investing.

What is the market cap of Fortis Healthcare, Sona BLW, Navin Fluorine and Ajanta Pharma?

Ans. As of 28 October 2026, Fortis Healthcare has a market cap of Rs 57,814 crore, Sona BLW has a market cap of Rs 57,251 crore, Navin Fluorine has a market cap of Rs 44,095 crore and Ajanta Pharma has a market cap of Rs 43,550 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on upper quarter of 52-week range stocks.

What are the risks of investing in upper quarter of 52-week range stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Sona BLW trades at a PE of 83.46 against an industry PE of 37.33, so earnings growth needs to hold up.

Why is Sona BLW trading at a PE of 83.46?

Ans. Sona BLW’s PE of 83.46 compares with an industry PE of 37.33. The market is paying a premium for profit growth of 14.86% a year since FY22, latest-quarter profit growth of 46.67% and FY26 revenue growth of 24.19%, which also means the stock is more sensitive if growth slows. Investors in upper quarter of 52-week range stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Fortis Healthcare, Sona BLW, Navin Fluorine and Ajanta Pharma?

Ans. As of the latest reported quarter, FII and DII together hold 57.43% of Fortis Healthcare (25.20% and 32.23%), 65.22% of Sona BLW (23.61% and 41.61%), 52.19% of Navin Fluorine (23.73% and 28.46%) and 29.57% of Ajanta Pharma (7.63% and 21.94%). Rising institutional holding is a useful signal in upper quarter of 52-week range stocks, though it should be read with earnings trends rather than on its own.